TACSTD2 and prostate carcinoma: In the context of prostate cancer, Trop2 is highly expressed in metastatic castration-resistant prostate cancer and Sacituzumab govitecan is currently tested in clinical trials for patients with metastatic prostate cancer15,17,30,31.